CD19/22 CAR T-cells in children and young adults with B-ALL: Final Phase 1 trial results
Sara Silbert(National Institutes of Health), Nirali Shah(National Cancer Institute), Constance M. Yuan(National Cancer Institute), Terry J. Fry(University of Colorado Anschutz Medical Campus), Alexander W. Rankin(National Institutes of Health), Toni Foley, Flavia Gava(National Institutes of Health), Bonnie Yates(National Institutes of Health), Naomi Taylor(National Institutes of Health), Haneen Shalabi(Center for Cancer Research), David F. Stroncek(Yale University), Lauren Little(Rush University), Hao‐Wei Wang(Fu Jen Catholic University), Christopher D. Chien, Alexandra Dreyzin(National Cancer Institute), Steven L. Highfill(National Institutes of Health)
Cited by 0
Related Papers
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
|Nature Communications|2016|435
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
|Nature Reviews Clinical Oncology|2022|324